Centers for Advanced Individual Medicine™
In addition to offering advanced genomic tests, the Centers for Advanced Individualized Medicine™ (CAIM) serve as an educational resource to keep CTCA oncologists up to date on this constantly evolving field of medicine and educate patients on the benefits, limitations and opportunities of advanced genomic testing in their particular situation. In addition to staying at the forefront of precision cancer care advances, CAIM™ partners regularly with peer institutions with sophisticated expertise in the field, to collaborate on furthering the quest for new treatment options.
If you and your oncologist decide you are a candidate for genomic testing, here’s how the process would work:
- A biopsy will be taken of your tumor.
- Cancer cells will be isolated and extracted from the biopsy, then their DNA will be sequenced in the lab.
- Highly sophisticated equipment will be used to scan the sequenced genetic profile for abnormalities that dictate how the tumor functions.
- The abnormalities will be analyzed in a lab to determine whether they match known mutations that may have responded to particular therapies or where evidence suggests there may be a potential treatment option not previously considered.
- If there’s a match, your oncologist may be able to use the results to suggest treatments that have been used in the past to target the same mutations.
- Your oncologist will explain the results to you and any indications for new treatment options, and together you will formulate a treatment plan targeted to your individual situation.
- If you or your caregivers have additional questions, CAIM will offer resources and educational guidance on this emerging field of medicine.
The future of cancer care is here, and CTCA is committed to combining advanced diagnostic technologies with personalized treatment options to pinpoint the therapies most likely to work for you. Advanced genomic testing is a tool we can use, today, in the ongoing search for better ways to treat cancer—not just for the general population, but for each and every patient.